Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902246 · ClinicalTrials.gov registry record · Phase 2
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06902246: Recruiting Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma, sponsored by University of Miami.
NCT06902246 is a Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06902246, a Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
Conditions Studied
Interventions
- DRUG Regorafenib
- RADIATION TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2031-01-05 |
| Phase | Phase 2 |
What NCT06902246 shows while recruiting
NCT06902246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Regorafenib is the first listed.
NCT06902246 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06902246 about?
NCT06902246 is a clinical study titled "Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma". The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
What is the current status of trial NCT06902246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-01-05. Estimated completion is 2031-01-05.
What conditions does trial NCT06902246 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06902246?
The interventions under investigation include: Regorafenib (DRUG), TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization (RADIATION).
Who is sponsoring clinical trial NCT06902246?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06902246 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06902246's enrollment target sits among peer trials
30 108th of 145 higher than 34 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI